ArticleJournal of cachexia, sarcopenia and muscle2024
Detection of cancer-associated cachexia in lung cancer patients using whole-body [
Article in Journal of cachexia, sarcopenia and muscle, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Revolutionizing cancer diagnosis and dose biodistribution: a meta-analysis of [68ga] FAPI- 46 vs. [18f] FDG imaging.Systematic reviews · 2025Pooled it
- Subcutaneous Adipose Tissue FDG Uptake is Associated with Systemic Inflammatory Indices Independent of Primary-Tumor Metabolic Burden in Breast Cancer.Molecular imaging and biology · 2026Article
- Pre-therapeutic prediction of cachexia in lymphoma patients using [European journal of clinical nutrition · 2026Article
- A network analysis of whole-body [European journal of nuclear medicine and molecular imaging · 2026Article
- Sharing a whole-/total-body [Scientific data · 2026Article
- Explainable AI in nuclear medicine.European journal of nuclear medicine and molecular imaging · 2026Article
- Hyper-selective explainability: an empirical case study of the utility of explainability in a clinical decision support system.AI and ethics · 2026Article
- Whole-Body [Scientific data · 2025Article
- Article
- Sharing a whole-/total-body [18F]FDG-PET/CT dataset with CT-derived segmentations: an ENHANCE.PET initiative.Research square · 2025Article
- Cancer-Associated Cachexia: Bridging Clinical Findings with Mechanistic Insights in Human Studies.Cancer discovery · 2025Review
- What Cachexia-Related Outcomes Are Measured in Lung Cancer Chemotherapy Clinical Trials?Cancers · 2025Article
- Detection of cancer-associated cachexia in lung cancer patients using whole-body [Journal of cachexia, sarcopenia and muscle · 2024Article
- Comment on 'Detection of Cancer-Associated Cachexia in Lung Cancer Patients Using Whole-Body [Journal of cachexia, sarcopenia and muscle · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundCancer-associated cachexia (CAC) is a metabolic syndrome contributing to therapy resistance and mortality in lung cancer patients (LCP). CAC is typically defined using clinical non-imaging criteria. Given the metabolic underpinnings of CAC and the ability of [
methodsThis multi-centre study included 345 LCP who underwent WB [
resultsThe three CAC categories displayed multi-organ differences in <SUV
conclusionsWB [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.